David Oh

David Oh, MD, PhD is an Associate Professor of Medicine at the University of California, San Francisco (UCSF) School of Medicine. He is a physician-scientist specializing in cancer immunotherapy with particular expertise in genitourinary malignancies, including prostate and bladder cancers. Dr. Oh sees patients in the Cancer Immunotherapy Program at UCSF and leads numerous early-phase clinical trials focused on adoptive cell therapies for solid tumors, including CAR-T and TCR therapies. His laboratory conducts translational research on cytotoxic immune effectors in anti-tumor responses and immune-related adverse events following immunotherapy.

• Harvard College AB 2000 Biochemical Sciences
• Stanford University School of Medicine MD/PhD 2011 Medicine, Physiology
• University of California, San Francisco Residency 2014 Internal Medicine
• University of California, San Francisco Fellowship 2017 Hematology/Oncology

Dr. Oh's research focuses on developing novel immunotherapies with enhanced activity and reduced toxicity for patients with solid cancers. His work spans high-resolution multiomic interrogation and functional validation using patient samples, as well as murine model systems. Recent publications highlight his expertise in CD4+ T cell function in antitumor immunity, immune-related adverse events, and predictive biomarkers for immunotherapy response. His research has shown particular promise in understanding the role of cytotoxic CD4+ lymphocytes in bladder cancer and developing strategies to manage immune checkpoint inhibitor colitis.

Analysis of Dr. Oh's recent publications reveals a strong focus on translational immunology with emphasis on T cell responses to cancer therapies. His work consistently bridges basic science and clinical applications, particularly in the areas of immune monitoring, biomarker development, and management of immunotherapy toxicities. The publications show increasing sophistication in analytical approaches, moving from traditional immunological techniques to advanced single-cell and spatial multi-omics methods.

• University of California, San Francisco Clinical Fellow Award 2015
• Conquer Cancer Foundation of American Society of Clinical Oncology Merit Award 2016
• Conquer Cancer Foundation Young Investigator Award 2017
• Bladder Cancer Advocacy Network Young Investigator Award 2018
• Prostate Cancer Foundation Young Investigator Award 2018
• Damon Runyon Cancer Research Foundation Clinical Investigator Award 2021

Dr. Oh leads the NIH-funded project 'Identification of circulating and tissue-specific autoimmune responses in checkpoint inhibitor-induced immune-related adverse events' (K08AI139375). His clinical trials portfolio includes studies of adoptive cell therapies, intratumoral immunotherapies, and next-generation cytokine therapies for solid tumors. He has mentored numerous trainees in the field of cancer immunology and regularly collaborates with researchers across multiple disciplines including immunology, urology, and gastroenterology. His laboratory maintains strong connections with clinical programs at UCSF, facilitating rapid translation of research findings into patient care.